Prophylactic Administration of Alpha Blockers for Prevention of Urinary Retention in Males Undergoing Inguinal Hernia Repair Under Spinal Anaesthesia.

Sponsor
Georgios Koukoulis (Other)
Overall Status
Completed
CT.gov ID
NCT03976934
Collaborator
University of Thessaly (Other)
100
2
2
20.9
50
2.4

Study Details

Study Description

Brief Summary

Open inguinal hernia repair is one of the most common surgical procedures. Despite the fact that different of anesthetic procedures are proposed as alternatives to spinal anesthesia, the combination of spinal anesthesia with open inguinal hernia repair is preferred from both surgeons and patients. One disadvantage of this combination is the high incidence of post-surgery urinary retention, especially in men above 50 years old. This complication is partially attribute to overstimulation of the a1 adrenergic receivers of the bladder and the prostate. Preoperative administration of elective a1 blockers could inhibit this effect without side effects, since this drugs don't have systemic effect.

Condition or Disease Intervention/Treatment Phase
Phase 1/Phase 2

Study Design

Study Type:
Interventional
Actual Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Prevention
Official Title:
Prophylactic Administration of Alpha Blockers for Prevention of Post Operative Urinary Retention in Males Undergoing Open Inguinal Hernia Repair Under Spinal Anaesthesia.
Actual Study Start Date :
Feb 1, 2020
Actual Primary Completion Date :
Oct 1, 2021
Actual Study Completion Date :
Oct 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Tamsulosin group

administration of 0,4mg of tamsulosin 24 hours before surgery and 0,4mg 6 hours before surgery

Drug: Tamsulosin
administration of tamsulosin tablets
Other Names:
  • omnic tocas
  • Placebo Comparator: Placebo group

    administration of placebo 24 and 6 hours before surgery

    Drug: Placebo oral tablet
    sugar pills

    Outcome Measures

    Primary Outcome Measures

    1. incidence of urinary retention [8 hours post surgery]

      inability to voluntarily void urine up to 8 hours post surgery

    Secondary Outcome Measures

    1. Prostate related Symptoms [Baseline]

      identification of Prostate related Symptoms as preoperative risk factor of post surgery urinary retention. For the assessment of the prostate related symptomatology will be used the International Prostate Symptom Score questionnaire

    2. Scrotal hernia Repair [Baseline, Inta-operative]

      evaluation of Scrotal hernia repair as preoperative risk factor of post surgery urinary retention.

    3. Duration of Surgery [Duration of Surgical procedure]

      Evaluation of the surgery duration as inta-operative risk factor of post surgery urinary retention.

    4. Use of opioids [24 hours]

      Evaluation of the peri-operative administration of iv opioids as a peri-operative risk factor of post surgery urinary retention.

    5. Iv fluid administration [24 hours]

      Evaluation of the peri-operative iv fluid administration as a peri-operative risk factor of post surgery urinary retention.

    6. Post-operative Pain [24 hours]

      Evaluation of the post operative pain as a risk factor of post surgery urinary retention. For the assessment of the pain will be used the Visual Analog Scale (VAS) score at 6, 12 and 24 hours after surgery. (VAS Score Scale from 0-10, 0 no pain, 10 max pain)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    50 Years and Older
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • unilateral inguinal hernia
    Exclusion Criteria:
    • ASA score >3

    • hypotension

    • prostatic hypertrophy

    • complicated inguinal hernia

    • neurological diseases

    • inguinal hernia repair under general or local anaesthesia

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University General Hospital of Larissa Larissa Greece 41110
    2 General Hospital Of Larissa Larissa Greece 41221

    Sponsors and Collaborators

    • Georgios Koukoulis
    • University of Thessaly

    Investigators

    • Study Chair: Konstantinos Tepetes, MD, PHD, University Hospital of Larisa and Medical School, University of Thessaly
    • Principal Investigator: Georgios D Koukoulis, MD, PhD, General Hospital of Larissa
    • Principal Investigator: Konstantinos Mpouliaris, MD, General Hospital of Larissa

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Georgios Koukoulis, General Surgery Consultant, General Hospital of Larissa
    ClinicalTrials.gov Identifier:
    NCT03976934
    Other Study ID Numbers:
    • 1725
    First Posted:
    Jun 6, 2019
    Last Update Posted:
    Nov 26, 2021
    Last Verified:
    Nov 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Georgios Koukoulis, General Surgery Consultant, General Hospital of Larissa
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 26, 2021